COMPASS THERAPEUTICS, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings
COMPASS THERAPEUTICS, INC. (CMPX) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings of -$556.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-05.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings · last filed 2021-03-05
- COMPASS THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2020-12-31 was $0.00.
- COMPASS THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2020-09-30 was $0.00.
- COMPASS THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2020 was -$556.00K.
- COMPASS THERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2019 was -$104.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $0.00 derived: sum of 2 quarters · filed 2021-03-05 | -$556.00K 10-K · filed 2021-03-05 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$556.00K 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | -$556.00K 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | -$104.00K 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |